Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil Post-trial Access for GALACTIC-HF Subjects
2020-003057-30Phase 3Terminated
- Sponsor
- Amgen
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF), sponsored by Amgen. Started Aug 2020; status: terminated.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2020-003057-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003057-30.